BRAF and melanoma: It seems that due to the relatively frequent occurrence of NF1 mutations in melanoma and the fact that the inactivation of this gene reduces the sensitivity of melanoma cells to both types of MAP kinase inhibitors (anti-BRAF and anti-MEK), genetic changes in this gene are a promising predictive marker in targeted therapy of skin melanoma.